-

Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio at SNMMI Annual Meeting

ATLANTA--(BUSINESS WIRE)--Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies.

Debuting at the 2025 SNMMI Annual Meeting

  • Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a groundbreaking, solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows.
  • Instadose®VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company: The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel.

Additional Featured Solutions from the Broader Mirion Portfolio

  • ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields​​. Demonstrations for applications including BioTrax™ QMS, NMIS™, and BioRx™ will be available throughout the SNMMI Annual Meeting.
  • Apex-Guard™ Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity.
  • Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo® Probe and RDS-Med™ Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™ Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™ Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand.

“As the nuclear medicine and molecular imaging landscape evolves, Mirion is committed to leveraging our deep expertise in ionizing radiation to serve our customers and ensure safe, efficient operations at every step,” said Luis Rivera, Executive Vice President of Mirion Medical. “From research to production to patient care, Mirion Medical and Mirion Technologies alike are developing solutions to drive higher quality. We look forward to demonstrating how these solutions can shape a more connected future.”

Commitment to Patient Care and Safety
Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.

About Mirion
Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. The Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries.

©2025 Mirion. All rights reserved. Instadose®VUE, BioTrax™ QMS, NMIS™, BioRx™, CSPevo™, Apex-Guard™, IC3™, and iCAM™ are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.

Contacts

For media inquiries:
Erin Schesny
media@mirion.com

For investor inquiries:
Eric Linn
ir@mirion.com

Mirion


Release Versions

Contacts

For media inquiries:
Erin Schesny
media@mirion.com

For investor inquiries:
Eric Linn
ir@mirion.com

More News From Mirion

Mirion to Present at Baird’s 2026 Global Industrial Conference

ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that Chairman and Chief Executive Officer, Thomas Logan, and Chief Financial Officer and Medical Group President, Brian Schopfer, will present at Baird’s 2026 Global Industrial Conference. The presentation will begin at 5:05 PM ET on Tuesday, November 10, 2026. The presentation will be webcast live at Mirion's Investor Relations Page where a webcast link will be displayed under the "Events and Presentations” section. An archive of the...

Mirion Announces Third Quarter 2026 Financial Results

ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the third quarter ended September 30, 2026. “Third quarter results showcase quarterly orders performance, an inflection in organic revenue growth, and a doubling of year-to-date adjusted free cash flow generation,” commented Mirion’s Chairman and Chie...

Mirion Extends Support of IAEA Mission to Advance Cancer Care Globally through Rays of Hope Donation

ATLANTA--(BUSINESS WIRE)--Mirion, a leading provider of advanced radiation safety solutions, has announced support for the International Atomic Energy Agency (IAEA) Rays of Hope initiative, which aims to help address disparities in access to quality cancer diagnosis and treatment in Low- and Middle-Income Countries (LMIC). This milestone builds on the partnership agreement signed between Mirion and the IAEA in September 2025, which formalized Mirion’s support for the Agency’s mission to enhance...
Back to Newsroom